[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"condition:primary-central-nervous-system-lymphoma":3},{"name":4,"total":5,"recruiting":5,"trials":6,"biomarkers":113,"states":118},"Primary Central Nervous System Lymphoma",17,[7,15,22,29,36,42,48,54,60,66,71,77,83,89,95,101,107],{"nct_id":8,"title":9,"phases":10,"status":12,"updated_at":13,"content_modified":14},"NCT07015242","A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma",[11],"Phase 2","RECRUITING","2026-08-26T02:17:12.307088Z","2026-06-16T05:54:07.930845Z",{"nct_id":16,"title":17,"phases":18,"status":12,"updated_at":20,"content_modified":21},"NCT03328078","CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R\u002FR PCNSL)",[19],"Phase 1\u002FPhase 2","2026-08-26T02:18:37.277498Z","2026-05-05T02:43:29.579158Z",{"nct_id":23,"title":24,"phases":25,"status":12,"updated_at":27,"content_modified":28},"NCT07104032","IGNITE: Study of Tirabrutinib vs Rituximab\u002FTemozolomide for Relapsed\u002FRefractory Primary Central Nervous System Lymphoma (PCNSL)",[26],"Phase 3","2026-08-26T02:17:05.997056Z","2026-05-05T02:43:29.543178Z",{"nct_id":30,"title":31,"phases":32,"status":12,"updated_at":34,"content_modified":35},"NCT07137494","A Study of MB-CART19.1 Cellular Therapy for People With Central Nervous System Lymphoma (CNSL)",[33],"Phase 1","2026-08-26T02:19:12.219640Z","2026-05-05T02:43:28.527499Z",{"nct_id":37,"title":38,"phases":39,"status":12,"updated_at":40,"content_modified":41},"NCT04421560","Pembrolizumab, Ibrutinib and Rituximab in PCNSL",[19],"2026-08-26T02:18:23.582895Z","2026-05-05T02:43:27.592804Z",{"nct_id":43,"title":44,"phases":45,"status":12,"updated_at":46,"content_modified":47},"NCT06175000","Maintenance Obinutuzumab in Treating Patients With Central Nervous System Lymphoma Who Have Achieved a Complete or Partial Response",[11],"2026-08-26T02:18:08.005333Z","2026-05-05T02:43:27.247939Z",{"nct_id":49,"title":50,"phases":51,"status":12,"updated_at":52,"content_modified":53},"NCT04906096","Paxalisib (GDC-0084) In Recurrent Or Refractory PCNSL",[11],"2026-08-26T02:19:18.331180Z","2026-05-05T02:43:26.973033Z",{"nct_id":55,"title":56,"phases":57,"status":12,"updated_at":58,"content_modified":59},"NCT06475235","Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSL",[33],"2026-08-26T02:17:22.153941Z","2026-05-05T02:35:31.897135Z",{"nct_id":61,"title":62,"phases":63,"status":12,"updated_at":64,"content_modified":65},"NCT05351593","Tafasitamab Plus Lenalidomide in Relapsed CNS Lymphoma",[19],"2026-08-26T02:15:33.331531Z","2026-07-19T19:36:05.117507Z",{"nct_id":67,"title":68,"phases":69,"status":12,"updated_at":52,"content_modified":70},"NCT05681195","Zanubrutinib With Pemetrexed to Treat Relapsed\u002FRefractory Primary and Secondary Central Nervous System (CNS) Lymphomas",[11],"2026-05-05T02:43:28.471359Z",{"nct_id":72,"title":73,"phases":74,"status":12,"updated_at":75,"content_modified":76},"NCT05098613","Preliminary Safety and Tolerability of CD19x22 CAR T Cells in Adolescent and Adult R\u002FR B-NHL Patients",[33],"2026-08-26T02:16:59.895916Z","2026-07-19T19:36:05.125264Z",{"nct_id":78,"title":79,"phases":80,"status":12,"updated_at":81,"content_modified":82},"NCT04792489","DALY II USA\u002F MB-CART2019.1 for DLBCL",[11],"2026-08-26T02:16:01.910993Z","2026-07-19T19:36:05.118465Z",{"nct_id":84,"title":85,"phases":86,"status":12,"updated_at":87,"content_modified":88},"NCT06712810","Q702 for the Treatment of Patients With Hematologic Malignancies",[33],"2026-08-26T02:16:20.336282Z","2026-05-05T02:43:29.581486Z",{"nct_id":90,"title":91,"phases":92,"status":12,"updated_at":93,"content_modified":94},"NCT04830137","A Study of NX-2127 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[33],"2026-08-26T02:17:33.002248Z","2026-05-05T02:43:29.192735Z",{"nct_id":96,"title":97,"phases":98,"status":12,"updated_at":99,"content_modified":100},"NCT03666000","Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed\u002FRefractory (r\u002Fr) Non-Hodgkin Lymphoma (NHL) and r\u002Fr B-cell Acute Lymphoblastic Leukemia (B-ALL)",[33],"2026-08-26T02:17:01.714035Z","2026-05-05T02:43:27.435593Z",{"nct_id":102,"title":103,"phases":104,"status":12,"updated_at":105,"content_modified":106},"NCT05131022","A Study of NX-5948 in Adults With Relapsed\u002FRefractory B-cell Malignancies",[33],"2026-08-26T02:16:41.943926Z","2026-05-05T02:43:26.916657Z",{"nct_id":108,"title":109,"phases":110,"status":12,"updated_at":111,"content_modified":112},"NCT04656431","Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma",[33],"2026-08-26T02:17:57.997171Z","2026-07-19T19:36:05.131317Z",[114],{"biomarker":115,"count":116,"slug":117},"CD19 Gene",3,"cd19-gene",[119,123,127,130,133,137,141,144,148,151,154,157,160,163,166,170,173,176,179,182,185],{"state":120,"count":121,"slug":122},"New York",10,"new-york",{"state":124,"count":125,"slug":126},"California",8,"california",{"state":128,"count":125,"slug":129},"Florida","florida",{"state":131,"count":125,"slug":132},"Massachusetts","massachusetts",{"state":134,"count":135,"slug":136},"Ohio",7,"ohio",{"state":138,"count":139,"slug":140},"Pennsylvania",6,"pennsylvania",{"state":142,"count":139,"slug":143},"Texas","texas",{"state":145,"count":146,"slug":147},"Arizona",5,"arizona",{"state":149,"count":146,"slug":150},"Colorado","colorado",{"state":152,"count":146,"slug":153},"Illinois","illinois",{"state":155,"count":146,"slug":156},"Maryland","maryland",{"state":158,"count":146,"slug":159},"Minnesota","minnesota",{"state":161,"count":146,"slug":162},"North Carolina","north-carolina",{"state":164,"count":146,"slug":165},"Washington","washington",{"state":167,"count":168,"slug":169},"Connecticut",4,"connecticut",{"state":171,"count":168,"slug":172},"New Jersey","new-jersey",{"state":174,"count":168,"slug":175},"Oregon","oregon",{"state":177,"count":168,"slug":178},"Tennessee","tennessee",{"state":180,"count":116,"slug":181},"Georgia","georgia",{"state":183,"count":116,"slug":184},"Utah","utah",{"state":186,"count":116,"slug":187},"Wisconsin","wisconsin"]